A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Trial Parameters
Brief Summary
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Eligibility Criteria
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Willingness to comply with all study procedures and be available for the duration of the trial 4. Have a performance status of 0 to 2 on the ECOG Performance Scale. 5. Life expectancy ≥12 weeks as per investigator discretion 6. Patients with histologically proven, relapsed or refractory HL or B-NHL as follows: 1. HL after failure of at least 1 prior line of systemic therapy 2. Primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line therapy 3. Other B-cell NHLs after failure of at least 2 prior lines of systemic therapy. The eligible types of B-cell NHLs are: i. Diffuse large B cell lymphoma ii. Follicular lymphoma iii. Marginal Zone lymphoma iv. Mantle Cell Lymphoma d. Indolent lymphoma are only eligible if they require systemic treatment e. Lymphocyte predominant HL are eligible Note: Formalin-fixed, paraffin embedde